Welcome to our dedicated page for SpyGlass Pharma news (Ticker: SGP), a resource for investors and traders seeking the latest updates and insights on SpyGlass Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SpyGlass Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SpyGlass Pharma's position in the market.
SpyGlass Pharma (Nasdaq: SGP) announced AMA approval of a new add-on Category III CPT code +X659T for attachment and insertion of an intraocular lens prosthesis-mounted drug-eluting implant, based on its Bimatoprost Drug Pad-IOL (BIM-IOL) System, used with existing cataract surgery codes.
The BIM-IOL System targets elevated intraocular pressure in open-angle glaucoma or ocular hypertension patients with cataracts and is in two Phase 3 trials, with enrollment expected to complete in 2027.
SpyGlass Pharma (Nasdaq: SGP) reported first quarter 2026 results and pipeline progress. Cash, cash equivalents and short-term investments were $251.0 million as of March 31, 2026, expected to fund operations through 2028.
Phase 1/2 BIM-IOL data showed 34% mean IOP reduction at 78-mcg, 98% of patients free from topical IOP-lowering drops and 100% achieving BCDVA 20/32 or better, with a safety profile comparable to routine cataract surgery. Parallel Phase 3 BIM-IOL trials SGP-005 and SGP-006 have begun surgeries, with enrollment completion expected in 2027. The BIM-DRS first-in-human trial is planned for the second half of 2026. Net loss was $13.8 million, or ($0.69) per share, versus $8.8 million, or ($3.96) per share, a year earlier.
SpyGlass Pharma (Nasdaq: SGP) reported positive clinical progress and strengthened finances after its February 2026 IPO that raised $172.5 million. The Phase 1/2 BIM-IOL System topline showed sustained IOP control and elimination of topical IOP-lowering drops in ~97% of participants at 12 months.
Phase 3 enrollment is underway, cash resources are expected to fund operations through 2028, and a BIM-DRS first-in-human trial is planned for H2 2026.
SpyGlass Pharma (NASDAQ: SGP) announced positive topline 12-month Phase 1/2 results for the BIM-IOL System on March 9, 2026. In 104 randomized patients (2:1:1), the 78-mcg and 39-mcg groups showed 34% and 42% mean IOP reductions at 8 a.m., versus 35% for control.
At 12 months 98% (78-mcg) and 96% (39-mcg) of evaluable patients were free of topical IOP medications; 100% achieved 20/32 or better BCDVA with mean BCDVA of 86 letters (≈20/20). AE rates were similar across arms; no serious ocular AEs. Two pivotal Phase 3 trials began randomizing in January 2026.
SpyGlass Pharma (Nasdaq: SGP) said its executive management team will host one-on-one meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026.
The meetings are management-led 1x1 investor sessions during the conference, offering direct Q&A opportunities.
SpyGlass Pharma (Nasdaq: SGP) closed its initial public offering of 10,781,250 shares, including full exercise of the underwriters’ option for 1,406,250 additional shares, at a public offering price of $16.00 per share on Feb. 9, 2026.
The aggregate gross proceeds were $172.5 million before underwriting discounts, commissions and offering expenses. SpyGlass Pharma began trading on the Nasdaq Global Select Market under the symbol SGP on Feb. 6, 2026. Joint book-runners were Jefferies, Leerink Partners, Citigroup and Stifel.
SpyGlass Pharma (Nasdaq: SGP) priced an initial public offering of 9,375,000 shares at $16.00 per share, generating approximately $150 million in gross proceeds before underwriting discounts and expenses. The company granted underwriters a 30-day option for an additional 1,406,250 shares.
SpyGlass Pharma common stock is expected to begin trading on the Nasdaq Global Select Market on February 6, 2026, with the offering expected to close on February 9, 2026, subject to customary closing conditions. The registration statement became effective January 30, 2026.